Johnson & Johnson logo

JNJ

Johnson & Johnson
NYSE
Healthcare
Drug Manufacturers - General
jnj.com
$.
$2.08(+0.78%)
LIVEupdated just now
O: $270.83H: $271.84L: $267.02

Market Cap

$645.68B

P/E Ratio

31.12

52W High

$276.47

52W Low

$173.33

B

Quality Score

JNJ scores 79/100 (B) — profitability is the strongest factor, valuation the weakest.

79

/ 100

See the full 7-factor breakdown with PRO.

Upgrade
More historical data is needed for full RSI, MACD, and Bollinger readings.

AI Technical Interpretation

PRO turns JNJ's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.

Upgrade to PRO

AI “Why Did It Move?”

Get a ranked, evidence-grounded read on what's likely driving JNJ's move today — news, earnings, analyst activity, sector context, and technicals combined.

Upgrade to PRO

Analyst Ratings
23 analysts

ConsensusBuy
Strong Buy5
Buy11
Hold6
Sell1
Strong Sell0
Avg price target+1.71%
$272.50from $267.93
Low $190.00Median $280.00High $305.00

Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.

AI Fair Value Estimate

Get an AI analyst's take on whether JNJ looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.

Upgrade to PRO

AI Earnings Preview

Next report 2026-10-13 · in 42 days

Consensus estimates

EPS

$2.43

Revenue

$25.19B

Recent EPS surprises

2026-06Beat +2%2026-03Beat +1%2025-12Miss -0%2025-09Beat +1%

Unlock the AI preview for JNJ

Get an AI analyst's read on the setup, what to watch, and risks heading into the print.

Upgrade to PRO
Post-Earnings Recap· reported 2026-06-30

Unlock the post-earnings recap for JNJ

Get an AI analyst's read on how the report went and how the stock reacted.

Upgrade to PRO

Dividend
Quarterly

Forward yield

2.00%

Annual / share

$5.36

Last ex-date

Aug 25, 2026

Last payment

Sep 8, 2026

Recent payments

Ex-date Aug 25, 2026$1.34
Ex-date May 26, 2026$1.34
Ex-date Feb 24, 2026$1.30
Ex-date Nov 25, 2025$1.30
Ex-date Aug 26, 2025$1.30
Ex-date May 27, 2025$1.30
Ex-date Feb 18, 2025$1.24
Ex-date Nov 26, 2024$1.24

Forward annual dividend from the declared rate (or latest payment × frequency) · via Yahoo Finance & Financial Modeling Prep.

AI Dividend Safety

Get an AI read on whether JNJ's dividend looks sustainable — earnings coverage, payout history, and the risks worth researching.

Upgrade to PRO

Insider Trading

No recent insider trading activity is available for JNJ.

Financial Statements

MetricFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$94.19B$88.82B$85.16B$79.99B$78.74B
Gross Profit$68.56B$61.35B$58.61B$55.39B$55.34B
Operating Income$25.60B$22.15B$23.41B$21.01B$20.94B
EBITDA$41.05B$24.78B$23.32B$26.61B$26.75B
Net Income$26.80B$14.07B$35.15B$17.94B$20.88B
EPS (Diluted)$11.03$5.79$13.72$6.73$7.81

Financial statements via Financial Modeling Prep. Figures as reported; not investment advice.

AI Stock Analysis

Unlock an in-depth, balanced bull/bear breakdown of JNJ — catalysts, risks, and a plain-language read on the fundamentals.

Upgrade to PRO

Investor Copilot Notebook

Keep a thesis on JNJ

Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.

Upgrade to PRO

Investment Thesis Timeline

See JNJ's full timeline

Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.

Upgrade to PRO
TradingView
Sponsored

Deeper technical charting, indicators, and pattern tools that complement XMarketPro's research.

Open advanced charts

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

TrendSpider
Sponsored

Automated technical analysis, charting, and pattern recognition for active traders.

Explore automated technical analysis

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Seeking Alpha
Sponsored

Another independent research perspective to compare against XMarketPro's own analysis.

Compare with additional research

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Interactive Brokers
Sponsored

A well-established U.S. brokerage for investors moving from research into execution.

Explore brokerage options

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

JNJ logo
About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Visit jnj.com

Key Statistics

Open
$270.83
Prev Close
$265.85
Day High
$271.84
Day Low
$267.02
Volume
1.73M
Market Cap
$645.68B
P/E Ratio
31.12
EPS
$8.61
Beta
0.23
Dividend Yield
+2.02%
52W High
$276.47
52W Low
$173.33
Analyst Target